黑龙江珍宝岛药业股份有限公司5%以上股东减持股份结果公告

Core Viewpoint - The major shareholders of Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. have completed their share reduction plan, resulting in both shareholders no longer holding more than 5% of the company's shares [3][5]. Group 1: Shareholder Information - Before the reduction plan, Baoding Junze Fanglong Equity Investment Center (Limited Partnership) held 55,792,905 shares, accounting for 5.93% of the total share capital, while Huzhou Saihan Equity Investment Partnership (Limited Partnership) held 47,098,180 shares, accounting for 5.01% [2]. Group 2: Reduction Plan Implementation - The reduction plan allowed Baoding Junze Fanglong to reduce up to 28,229,895 shares, which is not more than 3% of the total share capital, with a maximum of 9,409,965 shares through centralized bidding and 18,819,930 shares through block trading [4]. - Huzhou Saihan was permitted to reduce up to 9,409,965 shares through centralized bidding, which is also not more than 1% of the total share capital [4]. Group 3: Actual Reduction Results - Baoding Junze Fanglong reduced 9,028,305 shares through centralized bidding (0.96% of total share capital) and 6,924,700 shares through block trading (0.74% of total share capital) [5]. - Huzhou Saihan reduced 1,011,654 shares through centralized bidding (0.11% of total share capital) [5].